Human macrophage and dendritic cell-specific silencing of high-mobility group protein B1 ameliorates sepsis in a humanized mouse model
- 3 December 2012
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 109 (51) , 21052-21057
Abstract
Hypersecretion of cytokines by innate immune cells is thought to initiate multiple organ failure in murine models of sepsis. Whether human cytokine storm also plays a similar role is not clear. Here, we show that human hematopoietic cells are required to induce sepsis-induced mortality following cecal ligation and puncture (CLP) in the severely immunodeficient nonobese diabetic (NOD)/SCID/IL2Rγ −/− mice, and siRNA treatment to inhibit HMGB1 release by human macrophages and dendritic cells dramatically reduces sepsis-induced mortality. Following CLP, compared with immunocompetent WT mice, NOD/SCID/IL2Rγ −/− mice did not show high levels of serum HMGB1 or murine proinflammatory cytokines and were relatively resistant to sepsis-induced mortality. In contrast, NOD/SCID/IL2Rγ −/− mice transplanted with human hematopoietic stem cells [humanized bone marrow liver thymic mice (BLT) mice] showed high serum levels of HMGB1, as well as multiple human but not murine proinflammatory cytokines, and died uniformly, suggesting human cytokines are sufficient to induce organ failure in this model. Moreover, targeted delivery of HMGB1 siRNA to human macrophages and dendritic cells using a short acetylcholine receptor (AchR)-binding peptide [rabies virus glycoprotein (RVG)-9R] effectively suppressed secretion of HMGB1, reduced the human cytokine storm, human lymphocyte apoptosis, and rescued humanized mice from CLP-induced mortality. siRNA treatment was also effective when started after the appearance of sepsis symptoms. These results show that CLP in humanized mice provides a model to study human sepsis, HMGB1 siRNA might provide a treatment strategy for human sepsis, and RVG-9R provides a tool to deliver siRNA to human macrophages and dendritic cells that could potentially be used to suppress a variety of human inflammatory diseases.Keywords
This publication has 34 references indexed in Scilit:
- Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting CellsMolecular Therapy, 2011
- Therapeutic siRNA silencing in inflammatory monocytes in miceNature Biotechnology, 2011
- Novel Insights for Systemic Inflammation in Sepsis and HemorrhageMediators of Inflammation, 2010
- Targeted Delivery of siRNA to Macrophages for Anti-inflammatory TreatmentMolecular Therapy, 2010
- Lipid-like materials for low-dose, in vivo gene silencingProceedings of the National Academy of Sciences, 2010
- In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responsesNature Biotechnology, 2009
- Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammationNature, 2009
- Immunodesign of experimental sepsis by cecal ligation and punctureNature Protocols, 2008
- Bench-to-bedside review: High-mobility group box 1 and critical illnessCritical Care, 2007
- The Pathophysiology and Treatment of SepsisNew England Journal of Medicine, 2003